Cargando…
Safety concerns about intravenous iron therapy in patients with chronic kidney disease
Anaemia in chronic kidney disease (CKD) is managed primarily with erythropoiesis-stimulating agents (ESAs) and iron therapy. Following concerns around ESA therapy, intravenous (IV) iron is being administered more and more worldwide. However, it is still unclear whether this approach is safe at very...
Autores principales: | Del Vecchio, Lucia, Longhi, Selena, Locatelli, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792617/ https://www.ncbi.nlm.nih.gov/pubmed/26985378 http://dx.doi.org/10.1093/ckj/sfv142 |
Ejemplares similares
-
Chronic kidney disease in children
por: Becherucci, Francesca, et al.
Publicado: (2016) -
Incident chronic kidney disease: trends in management and outcomes
por: Perkins, Robert M., et al.
Publicado: (2016) -
Chronic kidney disease hotspots in developing countries in South Asia
por: Abraham, Georgi, et al.
Publicado: (2016) -
Noninvasive markers of arterial stiffness and renal outcomes in patients with chronic kidney disease
por: Guo, Xinru, et al.
Publicado: (2021) -
Chronic kidney disease in public renal practices in Queensland, Australia, 2011–2018
por: Hoy, Wendy E., et al.
Publicado: (2022)